Proteins and Peptides

23 Jun 2020 Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II
23 Jun 2020 FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
22 Jun 2020 SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II
18 Jun 2020 Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity
18 Jun 2020 Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus
18 Jun 2020 Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
18 Jun 2020 Agalsidase Beta BS I.V. Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in Molecular Genetics and Metabolism
16 Jun 2020 FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin
15 Jun 2020 Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise
15 Jun 2020 Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin
15 Jun 2020 Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial
13 Jun 2020 New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
13 Jun 2020 Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme
13 Jun 2020 Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects
12 Jun 2020 Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
12 Jun 2020 Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
11 Jun 2020 Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
11 Jun 2020 FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
09 Jun 2020 First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial
05 Jun 2020 Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
05 Jun 2020 Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial
02 Jun 2020 Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
01 Jun 2020 Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia
01 Jun 2020 Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine
01 Jun 2020 Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up